Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Takara Bio: Sales Down 3.0% due to Decline in Sales of Scientific Instruments
June 27, 2011
- Call For “Copayment Revision”Remains Unchanged in Revised SS Reform Plan
June 27, 2011
- NCC, Shimadzu Tie Up to Develop Advanced Cancer Treatment Technology
June 27, 2011
- Takeda Sues 18 Generic Companies for Actos Patent Infringement
June 27, 2011
- Compassionate Use of Unapproved Drugs to Require Clarification of Roles, Responsibilities
June 27, 2011
- Sangi Develops Oral Formulation for Cisplatin
June 27, 2011
- Taiyo's Acquisition by Teva Provides New Opportunity for GE Ind.: Mr Honda of Mylan
June 27, 2011
- Major Drugstore Chains Report Increased Sales in Dispensing Business
June 20, 2011
- Top-4 Generic Makers Report Double-digit Growth in Sales, Profits
June 20, 2011
- Korosho to Permit Telemarketing of OTC Drugs to Residents of Isolated Islands for 2 More Years
June 20, 2011
- Ain Pharmaciez Posts New Record-high Sales
June 20, 2011
- Sawai: Sales, Profits Up Driven by Good Sales to Pharmacies
June 20, 2011
- Takeda Launches Sonias Combination Tablet for Type 2 Diabetes
June 20, 2011
- Sales Down 5.8% for Ethical Drugs in April: Crecon Research & Consulting
June 20, 2011
- Towa: Double-digit Growth in Both Sales, Profits
June 20, 2011
- PAFSC Committee Turns Down Approval of Epogin for Anemia in Cancer Patients
June 20, 2011
- PMDA Should Develop Better Assessment Methods with Industry: Korosho Councilor Hirayama
June 20, 2011
- New Prescription of Actos Suspended in France, Germany due to Bladder Cancer Risk
June 20, 2011
- Development of Anti-obesity Drug Contrave Suspended in US
June 20, 2011
- Chuikyo to Resume Discussions on Next Round of Drug Pricing Reform on June 22
June 20, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…